Tebentafusp

Tebentafusp
Clinical data
Trade names	Kimmtrak
Other names	IMCgp100, tebentafusp-tebn
License data	US DailyMed: Tebentafusp;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous
ATC code	L01XX75 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1874157-95-5;
DrugBank	DB15283;
UNII	N658GY6L3E;
KEGG	D12296;

Tebentafusp, sold under the brand name Kimmtrak, is an anti-cancer medication used to treat uveal melanoma (eye cancer). Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. Tebentafusp is given by intravenous infusion.

The most common side effects include cytokine release syndrome, rash, pyrexia (fever), pruritus (itching), fatigue (tiredness), nausea, chills, abdominal pain (stomach pain), edema (swelling), hypotension (low blood pressure), dry skin, headache, and vomiting, and abnormal liver blood tests.

Tebentafusp was approved for medical use in the United States in January 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.